Biotech Pharmaceutical Sector Fights COVID-19 (STAB, PFE, MRNA, BNTX, LLY and NVAX)

Biotech Pharmaceutical stocks are building profits in 2022 while developing more effective COVID-19 vaccines and treatments for variants. Investors may buy these stocks now as new drugs reach the market

Biotech Pharmaceutical analysts see the pandemic evolving into an endemic. Profits are ahead as global countries seek COVID-19 vaccines. Biotech R&D for COVID-19 specialty vaccines offer investors profits as anti-COVID-19 drug candidates undergo clinical studies before final FDA approval. 

COVID-19 vaccines are a key investor opportunity in biotech pharmaceuticals. We are now at two years since then pandemic began. Biotech Pharmaceuticals created the vaccines to treat COVID-19 and its later variants. Now, leading Biotech sector companies are launching clinical studies designed to treat largely non-hospitalized but acute patients worldwide.

The catalyst for this sector for investors is profit and dividends. Statera Biopharma, Inc. (NASDAQ: STAB) is a clinical stage biopharmaceutical company studying treatment of patients with acute COVID-19 long-term infection. Place STAB stock on your Watch List as this compelling biotech research continues and profits are ahead.

Biotech Pharmaceutical Sector Soars As COVID-19 Fighter

— Best known is Pfizer (NYSE: PFE) which this week initiated a study for Paxlovid, its new oral anti viral pill for the treatment of COVID-19. The Phase II/III pediatric study of the pill is designed for non-hospitalized, mediatric and symptomatic patients. 

In December 2021, the FDA authorized emergency use of the pill in high risk adults and children at least 12 years of age and older. Paxlovid is the first oral anti viral pill to be studied in a pediatric clinical study.

STAB Studies Treatment Of Acute COVID-19 Infection Patients  

— Statera Biopharma, Inc. (NASDAQ: STAB) is a clinical stage biopharmaceutical company studying treatment of patients with acute COVID-19 infection. Investor timing is critical. STAB has filed with the FDA its Phase 1 Clinical Trial protocol for investigational treatment of long-haul COVID-19.

This is a pilot study of STAB’s drug STAT-205 treatment of long haul COVID-19. Michael K. Handley, CEO, says the company has a vibrant ‘clinical stage pipeline’ and it has recently submitted to the FDA a Phase 3 clinical trial protocol for its STAT-201 candidate for the treatment of pediatric Crohn’s Disease.

In its STAT-205 study, STAB is researching acute COVID-19 infection. STAB hopes to develop preliminary data from that study this year.

In revised preliminary financials for the year ended December 31, 2021, STAB now says it achieved positive shareholders’ equity as of the year end-date.

MRNA Studies For Omicron-Specific Booster Drug Candidate

— Moderna, Inc. (NASDAQ: MRNA), after developing a COVID-19 vaccine now named Spikevax is now in a mid-stage study of its Omicron-specific booster candidate. The company already has a Phase Three study scheduled in the U.K. 

MRNA has advance purchase agreements valued at $19 billion for its  COVID-19 vaccine with multiple countries for 2022. The Company believes COVID-19 will turn endemic in 2022 and says it will generate more sales in the second half of 2022 than in the first half. BioNTech Is Testing For Its Fourth Vaccine For COVID-19

—BioNTech (NASDAQ: BNTX) is testing for a fourth generation COVID-19 vaccine. The Biotech Pharmaceutical industry expects that the pandemic will turn endemic this year. So performance may be short-term lower than expected.

BNTX hit $19 billion in volume in 2021. It will report Q4 earnings later this month. Analysts do not expect the company to match 2021 sales, but see a growth spurt ahead by 2026. Both BNTX and Regeneron Pharmaceuticals (NASDAQ: REGN) together generated billions of dollars in sales from COVID-19 vaccines.

LLY COVID-19 Drug Reduces Risk In Hospitalized Patients

— Eli Lilly and Company (NYSE: LLY) has preliminary research from the U.K. that shows its drug Baricitinib successfully reduces the risk of death in hospitalized COVID-19 patients. The drug was originally developed as a rheumatoid arthritis treatment by Eli Lilly jointly with Incyte Corp.

NVAX Is Researching A COVID-19 Drug Candidate 

— Novavax (NASDAQ: NVAX) is researching a COVID-19 drug candidate, NVX:CoV2373. It has already secured approvals from multiple countries as well as an Emergency Use Listing from the WHO.

Biotech Stocks Can Pay Off Big

Biotech stocks offer investors drug candidates and innovative research that pays off big when commercially successful. 

Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies succeed. Link to more news at

Disclaimers: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall CGR. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by CGR., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
Country: United States